{"id":"cyclasol-topical-ocular-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation/burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A is a calcineurin inhibitor that reduces T-cell activation and pro-inflammatory cytokine production on the ocular surface. The CyclASol formulation uses a proprietary solubilization technology (Novaliq's VISIOMER platform) to deliver cyclosporine in an aqueous, preservative-free eye drop without requiring oil-based vehicles, improving tolerability and corneal bioavailability.","oneSentence":"CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:15.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ciclosporine (CsA)","Ciclosporine (CSA)"],"phase":"phase_3","status":"active","brandName":"CyclASol topical ocular, eye drops","genericName":"CyclASol topical ocular, eye drops","companyName":"Novaliq GmbH","companyId":"novaliq-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}